CAR T-cell (chimeric antigen receptor T-cell) has shown encouraging outcomes in the treatment of several cancers, including mantle cell lymphoma (MCL) that is a rare type of non-Hodgkin lymphoma (NHL) which begins in the lymph nodes. It is distinguished by cyclin D1 protein overexpression caused by a chromosomal translocation between the immunoglobulin heavy chain locus (IGH) and Cyclin D1 (CCND1) gene. In the case of MCL, excessive CCND1 is produced by B cells that are abnormal. Notably, CCND1 helps in the growth of B cells. Clinical characterization of MCL is done by its heterogeneity nature. The course of the disease ranges from indolent cases for which therapy is not essential for years to MCL that is highly aggressive in nature (requiring treatment), with the prognosis very limited. New targeted immunotherapy-based approaches, viz., CAR T-cell therapy, have already facilitated the improvement of the therapeutic options, particularly for the refractory or relapsing disease¹.